CHMP vurderer derfor, at forholdet mellem fordele og risici ved brugen af lægemidler, der indeholder stoffet paroxetin i de godkendte indikationer er positivt, og at markedsføringstilladelserne bør opretholdes i overensstemmelse med:
Therefore the CHMP considered that the benefit/ risk balance of paroxetine containing medicinal products in the agreed indications is favourable and the Marketing Authorisations should be maintained in accordance with the: